Cargando…

Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is a metabolic syndrome phenotype in the liver and thus obviously associated with metabolic abnormalities, including insulin resistance-related to hyperglycaemic and hyperlipidaemia. The prevalence of NAFLD is increasing worldwide. However, cur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwaki, Michihiro, Kessoku, Takaomi, Tanaka, Kosuke, Ozaki, Anna, Kasai, Yuki, Yamamoto, Atsushi, Takahashi, Kota, Kobayashi, Takashi, Nogami, Asako, Honda, Yasushi, Ogawa, Yuji, Imajo, Kento, Yoneda, Masato, Kobayashi, Noritoshi, Saito, Satoru, Nakajima, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Gastroenterology and Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277396/ https://www.ncbi.nlm.nih.gov/pubmed/35820743 http://dx.doi.org/10.1136/bmjopen-2021-060335

Ejemplares similares

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease
por: Kessoku, Takaomi, et al.
Publicado: (2020)

Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation
por: Tanaka, Kosuke, et al.
Publicado: (2022)

Comparison of long‐term prognosis between non‐obese and obese patients with non‐alcoholic fatty liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2022)

Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Endotoxins and Non-Alcoholic Fatty Liver Disease
por: Kessoku, Takaomi, et al.
Publicado: (2021)

The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD
por: Nogami, Asako, et al.
Publicado: (2022)

Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Nogami, Asako, et al.
Publicado: (2023)

Gastroesophageal varices evaluation using spleen‐dedicated stiffness measurement by vibration‐controlled transient elastography
por: Nagai, Koki, et al.
Publicado: (2021)

Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver
por: Niikura, Toshihiro, et al.
Publicado: (2020)

A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs
por: Kobayashi, Takashi, et al.
Publicado: (2022)

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
por: Yoneda, Masato, et al.
Publicado: (2022)

Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial
por: Ozaki, Anna, et al.
Publicado: (2022)

Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study
por: Ozaki, Anna, et al.
Publicado: (2020)

Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study
por: Kasai, Yuki, et al.
Publicado: (2022)

Current Research on the Pathogenesis of NAFLD/NASH and the Gut–Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome
por: Kobayashi, Takashi, et al.
Publicado: (2022)

Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan
por: Yoneda, Masato, et al.
Publicado: (2021)

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
por: Yoneda, Masato, et al.
Publicado: (2021)

Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)
por: Ozaki, Anna, et al.
Publicado: (2019)

Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease
por: Choden, Tenzin, et al.
Publicado: (2023)

Factors associated with poor compliance amongst hospitalized, predominantly adolescent pediatric Crohn’s disease patients
por: Cohen, Nathaniel A., et al.
Publicado: (2022)

Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype
por: Kessoku, Takaomi, et al.
Publicado: (2020)

Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care
por: Yoneda, Masato, et al.
Publicado: (2023)

Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs
por: Tomeno, Wataru, et al.
Publicado: (2020)

Effects of sleep quality on non-alcoholic fatty liver disease: a cross-sectional survey
por: Takahashi, Atsushi, et al.
Publicado: (2020)

Effect of endoscopic transpapillary biliary drainage with/without endoscopic sphincterotomy on post-endoscopic retrograde cholangiopancreatography pancreatitis in patients with biliary stricture (E-BEST): a protocol for a multicentre randomised controlled trial
por: Kato, Shin, et al.
Publicado: (2017)

Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study
por: Amin, Neeta B, et al.
Publicado: (2022)

Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved
por: Yoneda, Masato, et al.
Publicado: (2023)

Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials
por: Ben-Horin, Shomron, et al.
Publicado: (2019)

Efficacy and safety of lenvatinib–transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study
por: Oshita, Ko, et al.
Publicado: (2023)

Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease
por: Kawamura, Nobuyoshi, et al.
Publicado: (2022)

Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake
por: Ozaki, Anna, et al.
Publicado: (2021)

Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation
por: Yamamoto, Atsushi, et al.
Publicado: (2022)

Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma
por: Kurokawa, Suguru, et al.
Publicado: (2022)

Natural History of Chronic Intestinal Pseudo-obstruction and Need for Palliative Care
por: Tanaka, Kosuke, et al.
Publicado: (2023)

The NOTA study: non-operative treatment for acute appendicitis: prospective study on the efficacy and safety of antibiotic treatment (amoxicillin and clavulanic acid) in patients with right sided lower abdominal pain
por: Tugnoli, Gregorio, et al.
Publicado: (2011)

The European lactase persistence genotype determines the lactase persistence state and correlates with gastrointestinal symptoms in the Hispanic and Amerindian Chilean population: a case–control and population-based study
por: Morales, Eugenia, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_nv5mta6ovgtnlq8871902gb393